Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002101 · ClinicalTrials.gov registry record · Phase 3
A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
A Phase 3 study, sponsored by Pharmacia.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
NCT00002101: Completed Phase 3 study, sponsored by Pharmacia.
NCT00002101 is a Phase 3 study that has completed, run by Pharmacia. The registered enrollment target is 450 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002101, a Phase 3 study, has completed, sponsored by Pharmacia.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
Study Summary
To compare the efficacy of clarithromycin/ethambutol with placebo or with rifabutin at two different doses in reducing colony-forming units (CFUs) by 2 or more logarithms in patients with Mycobacterium avium Complex bacteremia and maintaining this response until 16 weeks post-randomization. To assess survival and comparative tolerability among the three treatment regimens.
Interventions
- DRUG Rifabutin
- DRUG Clarithromycin
- DRUG Ethambutol hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Phase | Phase 3 |
What the finished NCT00002101 record still lists
NCT00002101 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 3 interventions - of which Rifabutin is the first listed.
NCT00002101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002101 about?
NCT00002101 is a clinical study titled "A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo". To compare the efficacy of clarithromycin/ethambutol with placebo or with rifabutin at two different doses in reducing colony-forming units (CFUs) by 2 or more logarithms in patients with Mycobacterium avium Complex bacteremia and maintaining this response until 16 weeks post-randomization. To asses...
What is the current status of trial NCT00002101?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants.
What interventions are being tested in trial NCT00002101?
The interventions under investigation include: Rifabutin (DRUG), Clarithromycin (DRUG), Ethambutol hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002101?
This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002101's enrollment target sits among peer trials
450 837th of 2000 higher than 1,137 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank